PMC8257064_01
Disease development and treatment procedures.
OTT-14-3983-g0001.jpg
PMC8257064_01_OTT-14-3983-g0001.jpg
f0001
Figures 1-4 show the whole treatment process and the corresponding changes in PET-CT and computed tomography (CT) scan, as well as the changes in CA199 and carcinoembryonic antigen (CEA) levels.
Whole body positron emission computed tomography (PET-CT) and computed tomography (CT) of chest and abdomen. (A) PET-CT showed multiple larger lymph nodes in the right upper mesentery and abdominal aorta after first-line chemotherapy (SOX). (B and I) CT demonstrates no significant changes in retroperitoneal lymph nodes and new lung metastases when DP failed. (C) CT demonstrated progressive disease (PD) in the retroperitoneal lymph nodes when irinotecan failed. (D and J) CT scan indicated that the retroperitoneal lymph nodes were nearly disappeared and lung metastasis disappeared after four cycles of trastuzumab combined with chemotherapy (DCF) treatment. (E and K) PET-CT showed retroperitoneal newly metastatic lymph nodes and pulmonary newly metastatic nodules after trastuzumab combined with DCF. (F) After four cycles of apatinib combined with camrelizumab treatment, the size of retroperitoneal lymph nodes was significantly increased. (G, H and L) After three cycles of pyrotinib combined with capecitabine treatment, retroperitoneal lymph nodes were smaller than before, pulmonary metastasis disappeared after four cycles, and CT scan in August 2020 showed that retroperitoneal lymph nodes almost disappeared.
OTT-14-3983-g0002.jpg
PMC8257064_01_OTT-14-3983-g0002.jpg
f0002
Figures 1-4 show the whole treatment process and the corresponding changes in PET-CT and computed tomography (CT) scan, as well as the changes in CA199 and carcinoembryonic antigen (CEA) levels.
Change in carbohydrate antigen 199 (CA199) (U/mL) levels during entire treatment.
OTT-14-3983-g0003.jpg
PMC8257064_01_OTT-14-3983-g0003.jpg
f0003
Figures 1-4 show the whole treatment process and the corresponding changes in PET-CT and computed tomography (CT) scan, as well as the changes in CA199 and carcinoembryonic antigen (CEA) levels.
Change in carcinoembryonic antigen (CEA) (ng/mL) levels during entire treatment.
OTT-14-3983-g0004.jpg
PMC8257064_01_OTT-14-3983-g0004.jpg
f0004
Figures 1-4 show the whole treatment process and the corresponding changes in PET-CT and computed tomography (CT) scan, as well as the changes in CA199 and carcinoembryonic antigen (CEA) levels.